H&B launches FORMI™ Product containing SlimBiome®

OptiBiotix launches SlimBiome® in H&B’s 1,600-store network, but no sales figures disclosed.

What the company is saying

OptiBiotix Health plc announces the commercial launch of its SlimBiome® formulation in Holland & Barrett’s new FORMI™ weight management product. The company emphasizes the scale of H&B’s retail network, citing over 1,600 stores in 19 countries and more than 700 in the United Kingdom. The announcement highlights a 3-year non-exclusive trademark licence agreement signed in December 2025, allowing H&B to use SlimBiome® and LeanBiome® marks on new products. OptiBiotix frames SlimBiome® as clinically validated and positions the launch as a response to growing demand for non-drug weight management solutions, especially in the context of GLP-1 medication discontinuation. The company references external research and market forecasts, stating the global GLP-1 support supplements market was $1.8 billion in 2025 and is projected to reach $8.9 billion by 2034 at an 18.5% CAGR. CEO Stephen O’Hara claims the launch demonstrates growing industry recognition of SlimBiome® and signals further expansion opportunities.

What the data suggests

The only hard figures disclosed are external: H&B’s retail footprint (over 1,600 stores worldwide, 19 countries, over 700 in the UK) and the global GLP-1 support supplements market size ($1.8 billion in 2025, forecast to $8.9 billion by 2034, 18.5% CAGR). There are no sales, revenue, profit, or cash flow numbers for OptiBiotix or the new FORMI™ product. The announcement provides no evidence of market share, sell-through, or actual demand for SlimBiome® within H&B. Health claims for the product are described as on-pack statements, not as substantiated by new clinical data in this release. The 3-year trademark licence agreement with H&B is referenced, but no financial terms or minimum commitments are disclosed. The company’s claims about market opportunity and product validation are not supported by internal performance metrics or quantified outcomes.

Analysis

The announcement is upbeat, highlighting the launch of a new product in partnership with a major retailer and referencing a large, fast-growing market. However, the measurable progress is limited: while the product is stated to be available in stores and online, there are no disclosed sales figures, revenue, or profitability metrics for OptiBiotix. The only numerical data relates to the size and projected growth of the global GLP-1 support supplements market and the number of H&B stores, not to the company's own performance. Health claims for the product are presented as on-pack statements, not as substantiated clinical outcomes in this release. The tone is promotional, but the actual evidence of commercial traction or financial impact is absent. The forward-looking content (market forecasts) is not the main focus, but the lack of company-specific financials limits the strength of the signal.

Risk flags

• ●There is no disclosure of actual sales, revenue, or financial impact from the FORMI™ launch, leaving the scale of commercial benefit to OptiBiotix unproven. Without these figures, investors cannot assess whether the partnership is material or merely incremental.
• ●The announcement relies heavily on external market size and growth projections ($1.8 billion in 2025 to $8.9 billion by 2034 at 18.5% CAGR) rather than company-specific performance, which can create a disconnect between perceived opportunity and realized results.
• ●Health claims for SlimBiome® are described as on-pack statements, but no new clinical data or regulatory approvals are disclosed in this release, raising questions about the strength and differentiation of the product’s positioning.
• ●The 3-year trademark licence agreement with H&B is non-exclusive and lacks disclosed financial terms or sales targets, so there is no visibility on the potential scale or enforceability of the commercial relationship.

Bottom line

OptiBiotix’s announcement signals a potentially significant distribution channel for SlimBiome® via H&B’s 1,600-store network, but the absence of any disclosed sales, revenue, or margin data means investors have no basis to judge the financial impact. The company’s narrative leans on the rapid growth of the global GLP-1 support supplements market and the perceived credibility of its clinical claims, but these are not substantiated with new evidence or internal performance metrics. The non-exclusive nature of the H&B agreement and lack of financial detail further limit visibility on upside. For this to become actionable, OptiBiotix would need to report actual sales figures, market share gains, or margin contributions from the FORMI™ launch. Until then, the most important takeaway is that commercial access has expanded, but the value of that access remains unproven.

Announcement summary

(AIM: OPTI, OTCQB: OPTBF) OptiBiotix Health plc announced the launch of a new weight management product containing its clinically validated SlimBiome® formulation under Holland & Barrett's new own-brand, FORMI™. H&B has over 1,600 stores worldwide across 19 countries, including over 700 stores in the United Kingdom. In December 2025, OptiBiotix signed a new 3-year non-exclusive trademark licence agreement granting H&B rights to use SlimBiome® and LeanBiome® marks on new products containing OptiBiotix's patented mineral enriched dietary fibre and prebiotic ingredients. The new FORMI WEIGHT LOSS COMPLEX is available online and in H&B stores, sold as a Raspberry flavoured powdered drink sachet. The product has on-pack health claims of supporting weight management, helping to control blood sugar, and supporting satiety. The global GLP-1 support supplements market has been estimated at approximately $1,800,000,000 in 2025 and is forecast to reach $8,900,000,000 by 2034, representing a CAGR of approximately 18.5%. The launch of FORMI™ Weight Loss Complex follows H&B's May 2026 announcement of a weight management partnership with online pharmacy Phlo. Research from the University of Oxford (BMJ, Jan 2026) reported that people stopping weight-loss medication can regain weight more rapidly than those ending traditional diet-based programmes.

Disagree with this article?